Navidea biopharmaceuticals reports second quarter 2021 financial results

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the period ended june 30, 2021. “the company is prepared and looking forward to our meeting with the u.s. food and drug administration (“fda”) on september 1,” said mr. jed a. latkin, chief executive off
NAVB Ratings Summary
NAVB Quant Ranking